Table 1.
Summary of Patient Demographic, Clinicopathological, Inflammatory Mediator, and Body Composition Profile Data
| Characteristic | Patients, No. (%) (N = 219) |
|---|---|
| Age, median (IQR), y | 60 (53–69) |
| Sex | |
| Male | 155 (70.8) |
| Female | 64 (29.2) |
| BMI, mean ± SD, kg·m−2 * | 22.04 ± 3.25 |
| BMI, categories* | |
| Underweight | 25 (11.4) |
| Normal weight | 133 (60.7) |
| Overweight | 47 (21.5) |
| Obese | 9 (4.1) |
| Unclear | 5 (2.3) |
| BMI, mean ± SD, kg·m−2 ♰ | 21.56 ± 3.47 |
| BMI, categories♰ | |
| Underweight | 40 (18.3) |
| Normal weight | 122 (55.7) |
| Overweight | 47 (21.5) |
| Obese | 8 (3.7) |
| Unclear | 2 (0.9) |
| VFI, mean ± SD, (cm2/m2) | 23.37 ± 9.70 |
| SFI, mean ± SD, (cm2/m2) | 32.64 ± 13.21 |
| SMI, mean ± SD, (cm2/m2) | 40.43 ± 7.35 |
| VAT for men, mean ± SD, cm2 | 61.37 ± 21.22 |
| VAT for women, mean ± SD, cm2 | 59.67 ± 26.70 |
| SAT for men, mean ± SD, cm2 | 85.32 ± 33.37 |
| SAT for women, mean ± SD, cm2 | 95.10 ± 36.52 |
| NLR, mean ± SD * | 3.95 ± 4.22 |
| NLR, mean ± SD ♰ | 4.84 ± 4.39 |
| Diagnosis | |
| CRC | 49 (22.4) |
| EC | 34 (15.5) |
| GC | 47 (21.5) |
| HCC | 20 (9.1) |
| Others | 69 (31.5) |
| Clinical stage | |
| II | 10 (4.6) |
| III | 55 (25.1) |
| IV | 146 (66.7) |
| Unclear | 8 (3.7) |
| Treatment | |
| Nivolumab | 69 (31.5) |
| Pembrolizumab | 60 (27.4) |
| Camrelizumab | 45 (20.5) |
| Others | 45 (20.5) |
| PD-L1 | |
| Negative | 41 (18.7) |
| Positive (CPS) | 52 (23.7) |
| Unclear | 93 (42.5) |
CRC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; BMI, body mass index; NLR, neutrophil-to-lymphocyte ratio; SMI, skeletal muscle index; SFI, subcutaneous fat index; VFI, visceral fat index. SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue
*: at diagnosis; ♰: at the first cycle of ICI therapy